-
News | 2021.03.03
Primary Immunodeficiencies: launch of the second phase of the ATun-DIP's project in the North-Western regions of Tunisia
After more than three years of activities in the underprivileged regions of the Centre and South of Tunisia, the second phase of the ATun-DIP's project (Improvement of the management of Tunisian children suffering from Primary Immunodeficiency Diseases) started on February the 4th, 2021. The project, coordinated by the Institut Pasteur de Tunis in collaboration with several partners including the...
-
News | 2021.03.03
Argobio Studio
The Institut Pasteur is a scientific partner of Argobio Studio, a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years. Argobio will incubate early-stage, highly innovative therapeutic projects up to company creation and Series A venture funding in selected therapeutic areas.Prof. Stewart Cole, CEO of the Institut Pasteur, said: "...
-
News | 2021.03.08
Piecing together past epidemics by studying the human genome
Tuberculosis is one of the most deadly infectious diseases in the world, and it is the most deadly disease in Europe's history. It is generally caused by the Mycobacterium tuberculosis bacterium. Scientists have studied the impact of tuberculosis outbreaks on the human genome over the past 10,000 years.Our genome is partly shaped by natural selection. Genes that increase our chances of survival...
-
News | 2021.03.01
DECIDER: artificial intelligence to improve diagnosis and treatment of ovarian cancer
The Institut Pasteur's Systems Biology Group is a partner in a new international project on applications of artificial intelligence (AI) for the diagnosis and treatment of ovarian cancer. The project, entitled DECIDER, has been granted five-year funding by the European Union.The aim of the DECIDER project, funded by the European Union's Horizon 2020 program, is to improve personalized treatment...
-
News | 2021.03.11
2019-2023 Strategic Plan: Two new projects to boost the Institut Pasteur Innovation Accelerator
Two projects have been accepted into the Institut Pasteur Innovation Accelerator, an initiative to improve the development potential of the Institut Pasteur's research: a highly automated technological system involving bioassays and a partnership based on a French startup studio. The Institut Pasteur will be setting up the project Pfbioassays [in French] (Thierry Rose and Sébastien...
-
News | 2021.03.24
World Tuberculosis Day: ERA4TB accelerating the development of new treatment regimens
ERA4TB (the European Regimen Accelerator for Tuberculosis) is a 6-year public-private partnership with a total budget of over €200M that began in 2020 with the goal of accelerating the development of new treatment regimens for tuberculosis (TB). As part of the Innovative Medicines Initiative, ERA4TB brings together experts from academia and pharma, led by Stewart Cole (Institut Pasteur) and David...
-
News | 2021.03.22
Cell division: BST2, the common feature between viral infections and midbodies
The human body is made up of tens of thousands of billions of cells, all originating from the division of one parent cell into two daughter cells. Scientists from the Institut Pasteur set out to investigate midbodies, which are key cell division structures, and they identified the role of BST2, a restriction factor involved in viral infections.In order to divide, cells start by making identical...
-
Document de presse | 2021.03.09
ComCor: Study examining the sociodemographic, behavioral and practical factors associated with SARS-CoV-2 infection
The ComCor study is conducted by the Institut Pasteur in partnership with the French National Health Insurance Fund (CNAM), Ipsos and Santé publique France.Intermediate analysis, on March 1, 2021The ComCor study, which currently covers the period from October 1, 2020 to January 31, 2021, includes 77,208 participants with acute SARS-CoV-2 infection, excluding healthcare workers (8.2% of those...
-
Document de presse | 2021.03.26
COVID-19: analysis of the sensitivity of the UK (B.1.1.7) and South African (B.1.351) variants to SARS-CoV-2 neutralizing antibodies
The B.1.1.7 and B.1.351 variants of SARS-CoV-2 were first detected in the UK and South Africa respectively, and have since spread to many other countries. Scientists from the Institut Pasteur joined forces with Orléans Regional Hospital, Tours University Hospital, Créteil Intercommunal Hospital, Strasbourg University Hospital and Georges Pompidou European Hospital to study the sensitivity of...
-
Document de presse | 2021.03.23
SARS-CoV-2 variants of interest can infect mice: host range extended
SARS-CoV-2, the virus responsible for COVID-19, is capable of infecting some species, while others are naturally resistant to it. This determines the "host range" of the virus. The SARS-CoV-2 host range includes humans, non-human primates, hamsters, mink and cats. Since the start of the pandemic, mice and rats had proven to be resistant to SARS-CoV-2, because their ACE2 receptor, which allows the...
